Therapeutic Antibody Fragment Development Services

Antibody fragments offer better tumor penetration and less non-specific binding than full-length antibodies, resulting in unprecedented advances in the engineering of antibody fragment constructs for cancer therapeutic use. Alfa Cytology has specialized and advanced technology platforms to provide highly customized therapeutic antibody fragment development services.

Advantages of Therapeutic Antibody Fragments

Antibody fragments are partial components of antibody molecules, typically composed of specific regions of the heavy or light chains, such as the variable domains (Fv), single-chain variable fragments (scFv), or antigen-binding fragments (Fab). The therapeutic antibody fragment form offers a number of advantages over monoclonal antibodies (mAbs). They have great potential to improve drug efficacy and safety.

Alternative routes of administration - Their alternative routes of administration provide greater flexibility in therapy options, enabling targeted delivery to specific tissues or sites of action.

Binds antigens that mAbs do not bind - This feature expands the therapeutic potential for challenging targets.

Crosses the blood-brain barrier - Antibody fragments have the unique ability to bind antigens that are inaccessible to mAbs, expanding the therapeutic potential for challenging targets.

Enhanced stability - Antibody fragments can be stabilized under extreme conditions such as high temperature, high pressure, low pH, and low protease concentration.

Highly flexible - Antibody fragments provide high flexibility for modification and engineering, enabling the incorporation of additional functionalities such as drug conjugation or targeting multiple pathways simultaneously.

Less immunogenic - Antibody fragments exhibit reduced immunogenicity, minimizing the likelihood of immune responses and improving patient tolerance during therapy.

Fig.1 Graphic summary of antibody format engineering. (Lou, H., & Cao, X., 2022)

Our Services

Antibody fragment format is preferred over intact antibody. Alfa Cytology applies advanced recombinant antibody technology platforms to provide efficient and high-quality therapeutic antibody fragment development services to promote to facilitate the development of novel cancer therapies.

Multiple Antibody Fragment Formats

Variable region engineering offers a plethora of options for cancer therapy. Alfa Cytology utilizes a range of engineering methods to assist in the optimization of therapeutic antibodies and to assist customers in the development of multiple types of antibody fragments.

One-stop Therapeutic Antibody Development

At Alfa Cytology, we offer a one-stop solution for antibody development for cancer therapy, from antigen development to antibody optimization and characterization. Our experienced team of scientists and experts utilize cutting-edge technology and state-of-the-art equipment to deliver high-quality therapeutic antibodies to aid our clients' novel cancer therapy programs.

Workflow of Therapeutic Antibody Fragment Development

Our Advantages

Collaborate with us for your development needs of antibody fragments for cancer therapy and experience the convenience of a comprehensive and efficient development process with our scientific expertise and commitment to delivering breakthrough biologics. Please contact us for more information.

! For research use only.